Therapeutic Gain by Induction-concurrent Chemoradiotherapy and/or Accelerated Fractionation for Nasopharyngeal Carcinoma

Conditions Phase Intervention Type
  • Carcinoma
  • Nasopharyngeal Neoplasms
  • Nasopharyngeal Carcinoma
3
Drug
Capecitabine
Adjuvant chemotherapy using PF (5-Fluorouracil )
Induction chemotherapy using PF (5-Fluorouracil)

Eligibility

Ages Eligible for Study
18 years to 70 years
Genders Eligible for Study
Both

Keywords

Nasopharyngeal Carcinoma, Chemoradiotherapy, and Accelerated Fractionation

Sponsors

Other
hong Kong Cancer Fund
Other
The Hong Kong Anti-Cancer Society
Other
Hong Kong Nasopharyngeal Cancer Study Group Limited

Inclusion Criteria

- histologically proven nasopharyngeal carcinoma for primary treatment with radical
intent

- non-keratinizing or undifferentiated type

- stage III-IVB (by AJCC/UICC 6th edition)

- ECOG Performance status less or equal to 2

- Marrow: WBC >= 4 and platelet >=100

- Renal: creatinine clearance >=60

- Informed consent

Exclusion Criteria

- Primary treatment with palliative intent

- WHO type I squamous cell carcinoma or adenocarcinoma

- Evidence of distant metastases

- Patient is pregnant or lactating

- Prior malignancy except adequately treated basal cell or squamous cell skin cancer,
in-situ cervical cancer or other cancer for which the patient has been disease-free
for 5 years

Detailed Description

The objectives of this clinical study are threefold: 1. To compare the benefits in cancer control and survival obtained from adding induction-concurrent chemotherapy to radiation with those from adding concurrent-adjuvant chemotherapy to radiation. 2. To test whether replacing fluorouracil with Xeloda in combining with cisplatin in the chemotherapy plan will maintain or improve further the chemotherapy benefits while reducing the duration of hospital stay. 3. To see if accelerated fractionation radiotherapy can improve the outcome of patients as compared with conventional fractionation radiotherapy.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00379262

Overall Contact Backup

Anne W.M. Lee, FRCR (HK)
852-25954173

Locations

  • Cancer Center, Sun Yat Sen University
    Guangzhou, China
    (Recruiting)

    Contact info

    T.X. Lu, M.D.
    86-20 87343372
  • Department of Clinical Oncology, Queen Elizabeth Hospital
    Hong Kong, China
    (Recruiting)

    Contact info

    Roger K.C. Ngan, F.R.C.R.
    852-29586255
  • Department of Clinical Oncology, Queen Mary Hospital
    Hong Kong, China
    (Recruiting)

    Contact info

    Dora Kwong, F.R.C.R
    852-28554521
  • Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital
    Hong Kong, China
    (Recruiting)

    Contact info

    Anne W.M. Lee, F.R.C.R.
    852-25954173
  • Department of Clinical Oncology, Princess Margaret Hospital
    Hong Kong, China
    (Not yet recruiting)

    Contact info

    Ashley Cheng, F.R.C.R.
    852-29902803
  • Department of Clinical Oncology, Tuen Mun Hospital
    Hong Kong, China
    (Recruiting)

    Contact info

    Stewart Y. Tung, F.R.C.R
    852-24685098

See 1 more locations